Abnormal cannabidiol-sensitive receptor

The **abnormal cannabidiol-sensitive receptor** refers to an as-yet-unidentified receptor or set of receptors that mediate the effects of *abnormal cannabidiol* (Abn-CBD)—a synthetic isomer of cannabidiol—that are independent of the classical cannabinoid receptors CB1 and CB2[1][3][5][6][7]. Originally characterized pharmacologically by its role in vasodilation (relaxation of blood vessels) and anti-inflammatory effects—such as microglial cell migration and attenuation of pro-inflammatory mediator release—this receptor has not been cloned or definitively identified. Extensive pharmacological and genetic evidence suggests that the actions of Abn-CBD (and the related compound O-1602) are mediated through non-CB1, non-CB2 G protein-coupled receptors, with GPR18 and GPR55 being the main candidates[1][3][5][6][7]. However, the literature remains inconsistent regarding which of these orphan GPCRs represents the true "abnormal cannabidiol-sensitive receptor," with some experiments supporting a major role for GPR18, others for GPR55, and some suggesting additional unidentified GPCRs may be involved[1][3][7]. The target is implicated in various biological processes including endothelial function, anti-inflammatory responses, and cancer cell regulation, but further research is required to confirm its molecular identity and clarify its therapeutic relevance[1][3][6][7]. **Important note**: There is a fundamental problem with this target as currently named—**“abnormal cannabidiol-sensitive receptor”** is a functional, not a molecular, designation. The most likely molecular candidates for this activity are **GPR18** and **GPR55**[1][3][7], but no official gene, protein, or receptor named “abnormal cannabidiol-sensitive receptor” exists in standard nomenclature. The term is therefore not appropriate as a canonical molecular entity and is not suitable for structured databases without mapping to specific targets such as GPR18 or GPR55.

Other names

Other cannabinoid receptornon-CB1/non-CB2 cannabinoid receptorputative abn-CBD receptor

Agonism of G protein-coupled signaling pathways leading to vasodilation and modulation of inflammation (by abn-CBD and O-1602)